Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook
Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.